{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Revolution Medicines, Inc."},"Symbol":{"label":"Symbol","value":"RVMDW"},"Address":{"label":"Address","value":"700 SAGINAW DRIVE, REDWOOD CITY, California, 94063, United States"},"Phone":{"label":"Phone","value":"+1 650 481-6801"},"Industry":{"label":"Industry","value":null},"Sector":{"label":"Sector","value":null},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs."},"CompanyUrl":{"label":"Company Url","value":"https://www.revmed.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Jan Smith","title":"Chief Scientific Officer"},{"name":"Margaret A. Horn","title":"Chief Operating Officer"},{"name":"Mark A. Goldsmith","title":"Chairman, President & Chief Executive Officer"},{"name":"Stephen M. Kelsey","title":"President-Research & Development"},{"name":"Walter Reiher","title":"Chief Information Officer"},{"name":"Wei Lin","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}